B7-H3-mediated tumor immunology: Friend or foe?

International Journal of Cancer

Volumn 134, Issue 12, 2014, Pages 2764-2771

  Wang, Ling ^a   Kang, Fu Biao ^b   Shan, Bao En ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b BETHUNE INTERNATIONAL PEACE HOSPITAL   (China)

Author keywords

B7 H3; costimulatory molecule; tumor immunology

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; B7 HOMOLOG 3 PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B7 H3; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM TUMOR; CHEMOSENSITIVITY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GROWTH RATE; HUMAN; IMMUNOMODULATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR INVASION;

B7-H3; COSTIMULATORY MOLECULE; TUMOR IMMUNOLOGY;

B7 ANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; NEOPLASMS; TUMOR ESCAPE;

EID: 84898001946     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28474     Document Type: Review

References (64)

1. Finn OJ,. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012; 23 (Suppl 8): viii6-9.
2. Shi H, Liu L, Wang Z,. Improving the efficacy and safety of engineered T cell therapy for cancer. Cancer Lett 2013; 328: 191-7.
3. Alpdogan O, van den Brink MR,. Immune tolerance and transplantation. Semin Oncol 2012; 39: 629-42.
4. Turtle CJ, Hudecek M, Jensen MC, et al. Engineered T cells for anti-cancer therapy. Curr Opin Immunol 2012; 24: 633-9.
5. Poirier N, Blancho G, Vanhove B,. A more selective costimulatory blockade of the CD28-B7 pathway. Transpl Int 2011; 24: 2-11.
6. Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001; 2: 269-74.
7. Loos M, Hedderich DM, Friess H, et al. B7-h3 and its role in antitumor immunity. Clin Dev Immunol 2010; 2010: 683875.
8. Yi KH, Chen L,. Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev 2009; 229: 145-51.
9. Sun M, Richards S, Prasad DV, et al. Characterization of mouse and human B7-H3 genes. J Immunol 2002; 168: 6294-7.
10. Steinberger P, Majdic O, Derdak SV, et al. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol 2004; 172: 2352-9.
11. Duan H, Huang M,. Genome-wide identification and evolutionary analysis of B7-H3. Int J Data Min Bioinform 2012; 6: 292-303.
12. Sun J, Fu F, Gu W, et al. Origination of new immunological functions in the costimulatory molecule B7-H3: the role of exon duplication in evolution of the immune system. PloS One 2011; 6: e24751.
13. Ling V, Wu PW, Spaulding V, et al. Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics 2003; 82: 365-77.
14. Nygren MK, Tekle C, Ingebrigtsen VA, et al. B7-H3 and its relevance in cancer; immunological and non-immunological perspectives. Front Biosci (Elite Ed) 2011; 3: 989-93.
15. Suh WK, Gajewska BU, Okada H, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 2003; 4: 899-906.
16. Xu H, Cheung IY, Guo HF, et al. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res 2009; 69: 6275-81.
17. Wang J, Chong KK, Nakamura Y, et al. B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J Invest Dermatol 2013; 133: 2050-8.
18. Zhou Z, Luther N, Ibrahim GM, et al. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J Neuro-Oncol 2013; 111: 257-64.
19. Xu YH, Zhang GB, Wang JM, et al. B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis. Saudi Med J 2010; 31: 980-6.
20. Yamato I, Sho M, Nomi T, et al. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 2009; 101: 1709-16.
21. Crispen PL, Sheinin Y, Roth TJ, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 2008; 14: 5150-7.
22. Ingebrigtsen VA, Boye K, Tekle C, et al. B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. Int J Cancer 2012; 131: 2528-36.
23. Zang X, Sullivan PS, Soslow RA, et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 2010; 23: 1104-12.
24. Arigami T, Narita N, Mizuno R, et al. B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg 2010; 252: 1044-51.
25. Wu CP, Jiang JT, Tan M, et al. Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J Gastroenterol 2006; 12: 457-9.
26. Brunner A, Hinterholzer S, Riss P, et al. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis. Gynecol Oncol 2012; 124: 105-11.
27. Sun X, Vale M, Leung E, et al. Mouse B7-H3 induces antitumor immunity. Gene Ther 2003; 10: 1728-34.
28. Luo L, Chapoval AI, Flies DB, et al. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol 2004; 173: 5445-50.
29. Luo L, Qiao H, Meng F, et al. Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas. Int J Cancer 2006; 118: 1823-30.
30. Ma L, Luo L, Qiao H, et al. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J Hepatol 2007; 46: 98-106.
31. Lupu CM, Eisenbach C, Kuefner MA, et al. An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo. J Gastrointest Surg 2006; 10: 635-45.
32. Lupu CM, Eisenbach C, Lupu AD, et al. Adenoviral B7-H3 therapy induces tumor specific immune responses and reduces secondary metastasis in a murine model of colon cancer. Oncol Rep 2007; 18: 745-8.
33. Hashiguchi M, Kobori H, Ritprajak P, et al. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc Natl Acad Sci USA 2008; 105: 10495-500.
34. King RG, Herrin BR, Justement LB,. Trem-like transcript 2 is expressed on cells of the myeloid/granuloid and B lymphoid lineage and is up-regulated in response to inflammation. J Immunol 2006; 176: 6012-21.
35. de Freitas A, Banerjee S, Xie N, et al. Identification of TLT2 as an engulfment receptor for apoptotic cells. J Immunol 2012; 188: 6381-8.
36. Chen X, Quinn EM, Ni H, et al. B7-H3 participates in the development of experimental pneumococcal meningitis by augmentation of the inflammatory response via a TLR2-dependent mechanism. J Immunol 2012; 189: 347-55.
37. Loos M, Hedderich DM, Ottenhausen M, et al. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 2009; 9: 463.
38. Castriconi R, Dondero A, Augugliaro R, et al. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci USA 2004; 101: 12640-5.
39. Roth TJ, Sheinin Y, Lohse CM, et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 2007; 67: 7893-900.
40. Zang X, Thompson RH, Al-Ahmadie HA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA 2007; 104: 19458-63.
41. Chavin G, Sheinin Y, Crispen PL, et al. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res 2009; 15: 2174-80.
42. Parker AS, Heckman MG, Sheinin Y, et al. Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1343-9.
43. Sun J, Chen LJ, Zhang GB, et al. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother 2010; 59: 1163-71.
44. Boland JM, Kwon ED, Harrington SM, et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer 2013; 14: 157-63.
45. Sun TW, Gao Q, Qiu SJ, et al. B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence. Cancer Immunol Immunother 2012; 61: 2171-82.
46. Katayama A, Takahara M, Kishibe K, et al. Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumor metastasis and prognosis. Int J Oncol 2011; 38: 1219-26.
47. Sun Y, Wang Y, Zhao J, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 2006; 53: 143-51.
48. Mahnke K, Ring S, Johnson TS, et al. Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation. Eur J Immunol 2007; 37: 2117-26.
49. Bicknell AA, Cenik C, Chua HN, et al. Introns in UTRs: why we should stop ignoring them. Bioessays 2012; 34: 1025-34.
50. Lemke D, Pfenning PN, Sahm F, et al. Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. Clin Cancer Res 2012; 18: 105-17.
51. Chen C, Shen Y, Qu QX, et al. Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response. Exp Cell Res 2013; 319: 96-102.
52. Liu C, Liu J, Wang J, et al. B7-H3 expression in ductal and lobular breast cancer and its association with IL-10. Mol Med Rep 2013; 7: 134-8.
53. Schneider T, Hoffmann H, Dienemann H, et al. Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3. J Thorac Oncol 2011; 6: 1162-8.
54. Chen YW, Tekle C, Fodstad O,. The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. Curr Cancer Drug Targets 2008; 8: 404-13.
55. Yuan H, Wei X, Zhang G, et al. B7-H3 over expression in prostate cancer promotes tumor cell progression. J Urol 2011; 186: 1093-9.
56. Liu H, Tekle C, Chen YW, et al. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther 2011; 10: 960-71.
57. Zhao X, Zhang GB, Gan WJ, et al. Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma. Oncol Lett 2013; 5: 805-12.
58. Hellstrom I, Brankovan V, Hellstrom KE,. Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc Natl Acad Sci USA 1985; 82: 1499-502.
59. Steplewski Z, Lubeck MD, Koprowski H,. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 1983; 221: 865-7.
60. Mayer P, Handgretinger R, Bruchelt G, et al. Activation of cellular cytotoxicity and complement-mediated lysis of melanoma and neuroblastoma cells in vitro by murine antiganglioside antibodies MB 3.6 and 14.G2a. Melanoma Res 1994; 4: 101-6.
61. Onda M, Wang QC, Guo HF, et al. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res 2004; 64: 1419-24.
62. Luther N, Cheung NK, Dunkel IJ, et al. Intraparenchymal and intratumoral interstitial infusion of anti-glioma monoclonal antibody 8H9. Neurosurgery 2008; 63: 1166-74; discussion 74.
63. Luther N, Cheung NK, Souliopoulos EP, et al. Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38. Mol Cancer Ther 2010; 9: 1039-46.
64. Kramer K, Kushner BH, Modak S, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neuro-Oncol 2010; 97: 409-18.